Leukemia (2013) 27, 236-238; doi:10.1038/leu.2012.166 HOX homeobox transcription factors are not only master regulators of segment identity but also instrumental for proper blood formation (reviewed in Argiropoulos and Humphries 1 and Eklund 2 ). The physiology of hematopoietic stem and progenitor cells (HSPC) is under the direct control of HOX proteins. In particular, members of the 'HOX-A' and 'HOX-B' paralog groups are predominantly expressed in HSPC. Differentiation requires a downregulation of HOX genes and mature blood cells usually do not express HOX proteins any more. An abnormal HOX activity and, concomitantly, a block of differentiation are frequently observed in malignant hematopoiesis, thus qualifying HOX members as bona fide oncogenes.
Despite their importance in hematopoiesis, little is known about the HOX-subordinate pathways that are crucial for HSPC biology and leukemogenesis. A few studies have been published trying to identify HOX target genes in hematopoietic cells. [3] [4] [5] One recurrent problem is the multitude of genes that are under control of the HOX 'master regulators'. It is difficult to discriminate the 'driver' genes with importance in hematopoiesis from 'bystanders' that may be true HOX targets but have less impact on HSPC development. In this study we tried to address this problem by identifying a common gene expression pattern shared between HOXA1 and Hoxa9, two unrelated, yet both transforming HOX proteins. 6 As shown previously, 6 the labial-type HOXA1, as well as the abdominal-like HOXA9, transforms primary hematopoietic progenitors into immortalized myeloblasts. Therefore we reasoned that genes essential for myeloid transformation should be triggered by both HOX proteins in a similar fashion and hence these genes should be enriched within the common targets. To investigate this hypothesis we used tamoxifen (TAM)-inducible derivatives of HOXA1 and Hoxa9 created by fusion of a modified estrogenligand binding domain (ER) as reported previously. 6 (Hoxa9 shares 97% homology with human HOXA9; therefore we decided to use an existent murine clone.) As expected, transduction 7 of progenitor cells with both HOX derivatives leads to the immortalization of cytokine-dependent, myeloblastic populations that could be cultivated in medium supplemented with 100 ng/ml SCF, 10 ng/ml each of IL-3, IL-6, GM-CSF, and 100 nM 4-hydroxy-TAM. Importantly, these cells did not apoptose in the absence of TAM, but initiated a normal program of differentiation, terminating with the appearance of mature granulocytes and macrophages within approximately 1 week (data not shown). Four individual cell lines were created for each HOX construct from different donor animals. RNA was isolated with TAM present and 72 h after TAM withdrawal. This schedule was chosen because first significant changes in expression of several differentiation genes became detectable at that time point. Comparison of the expression profiles (raw data deposited at ArrayExpress under accession number E-MEXP-3648) revealed 948 and 374 genes that were significantly (change 41.7-fold, Po0.1) upregulated by HOXA1 and Hoxa9, respectively. A similar number of transcripts with opposite behavior could be detected (731 and 441 genes increased expression after HOX inactivation in HOXA1 and Hoxa9 cells). Among all HOX-responsive transcripts, a core group of 61 upregulated and 57 downregulated genes was shared by HOXA1 and Hoxa9. This included the myeloblastosis oncogene c-Myb that had been demonstrated to be an essential component of HOX-induced oncogenic pathways. 8 There was a high concordance between the genes identified in our study (66% for upregulated and 72% for downregulated targets) and those of Huang et al. 4 Within the common HOXA1/Hoxa9 targets the known oncogene vav2 caught our interest because Vav2 is a guanine-exchange factor for the small GTPase Rac1 and this factor has been implicated in MLLrearranged leukemia 9, 10 where MLL fusions work at least in part through upregulation of HOX genes.
Vav2 RNA and Vav2 protein were quantified by quantitative reverse transcriptase-PCR and western blotting in HOXA1/ Hoxa9-transformed cells cultivated with TAM and 72 h after TAM deprivation (Figures 1a and b) . Vav2 transcripts were reduced to approximately 20% of initial levels and also Vav2 protein dropped significantly in TAM-free medium. The genomic area upstream of the vav2 transcription initiation site contains several potential Pbx/Hox-and Meis/Hox-binding sites between À 1 and À 3 kb ( Figure 1c ). ChIP analysis was performed with primer pairs flanking these regions. An additional primer was placed into an X-chromosome satellite sequence as negative control. Significant enrichment of HOXA1-ER and Hoxa9-ER was detected at all potential binding sites. Owing to the technical resolution of the ChIP analysis (fragment size B500-800 bp), the primer pair at À 2 kb could also detect the occupation of neighboring Pbx/ HOX sites. Indeed the highest HOX enrichment scores were obtained for the region at À 2 kb. Anti-ER-specific antibodies precipitated up to 10-fold more DNA in HOXA1-ER-transformed cells compared with the control experiments. In Hoxa9-ER populations a 20-fold enrichment of this genomic region was detected, arguing strongly for a direct regulation of vav2 by HOX/ Pbx and/or HOX/Meis.
Next we checked if the corresponding sequences confer HOX responsiveness to a heterologous gene. For that purpose the putative vav2 promoter from position À 3081 to þ 1 relative to the transcription start was cloned into a luciferase reporter (pGL3). The construct was introduced into the embryonal carcinoma cell line P19 because these cells, in contrast to many other cell lines, have been demonstrated to be permissive for HOX-mediated transactivation.
11 Expression plasmids for HOXA1, Hoxa9 and the HOX cofactors Meis1 and Pbx1 were cotransfected individually or in combinations. Consistent with a promoter under HOX control, the transfection of each HOX protein and/or cofactor had an independent and cumulative effect on promoter output (Figure 1d) . Although total transactivation rates were moderate, they were significant and in the range of what had been obtained in similar experiments with other HOX-dependent promoter/ enhancer elements. 4, 5 Therefore these results are consistent with a direct regulation of vav2 by HOXA1 and Hoxa9.
Subsequently we tested if also Rac1 activity is controlled by HOX activity. Active Rac-GTP can be specifically precipitated by a GST-fusion with the Rac downstream partner PAK (p21 proteinCdc42/Rac-activated kinase) as described in Giehl et al. 12 and Figure 2a . Lysates of HOXA1-ER and Hoxa9-ER cells were prepared from cultures in TAM and 72 h after transfer to TAM-free media. After incubation with GST-PAK and thorough washing, the bound material was analyzed by a Rac1-specific immunoblot alongside input controls (Figure 2b ). Whereas total Rac1 levels did not change significantly, Rac1-GTP amounts were clearly correlated to HOX activity. Although HOXA1-ER-transformed cells contained lower concentrations of active Rac1-GTP than their Hoxa9-ER Accepted article preview online 20 June 2012; advance online publication, 13 July 2012 counterparts, control of active Rac1 by HOXA1 was still discernible. As HOX-dependent Rac1 activity might be induced also by other HOX targets, we wanted to determine the specific contribution of vav2 towards this phenomenon. For this purpose vav2 knockout mice were obtained. 13 Vav2 deletion is not associated with any obvious phenotype. This was also reflected by the fact that vav2 À / À bone marrow cells were indistinguishable from wild-type cells in transformation experiments (Figure 2c ). Cell lines could be derived from HOXA9-transformed vav2 À / À progenitors although Vav2 protein was undetectable in immunoblots. Vav2 À / À lines, however, contained significantly lower levels of Rac1-GTP (Figure 2d ). Densitometric quantification in three independently derived knockout lines revealed a reduction of Rac1-GTP to 18±10% (mean±s.d., n ¼ 3) of wild-type levels (data not shown). Active Rac1 concentrations could be largely restored by complementation with VAV2 (the human version with 95% homolog to the mouse protein was used because the corresponding mouse cDNA could not be obtained from a cDNA repository). Therefore Vav2 was likely the predominant determinant of Rac1 activity in this cell type.
Finally, transplantation experiments were set up to find out if leukemia biology is affected by HOX-mediated control of vav2. For this purpose wild-type and vav2 À / À bone marrow progenitors were simultaneously transduced with HOXA9 and the HOX cofactor Meis1 or in addition also with VAV2 as control. As expected, Rac1 activity was dependent on Vav2 in HOX/Meis double-transduced cells. Rac1-GTP was below detection limit in vav2
À / À cells and complementation with VAV2 rescued part of this activity (data not shown). In spite of this, there was no significant difference in disease latency regardless of the À / À cells were transduced with the cDNA for human VAV2 and Rac1 activity was detected as described above.
Vav2/ Rac1 status after transplantation into syngenic, lethally irradiated recipients (median survival 38 ± 3 days). However, that was concordant with a very recent study 14 published during preparation of this manuscript that showed that Rac2 rather than Rac1 influences leukemia latency. Indeed Rac2-GTP levels in HOX-transformed cells did not correlate with the vav2 status (not shown). Only the spleen weight of the diseased animals was significantly different in vav2 À / À transplants (270±64 mg, mean ± s.d., n ¼ 7) compared with wild-type (349 ± 83 mg, n ¼ 7, P ¼ 0.04) and VAV2-complemented cells (399 ± 70 mg, n ¼ 5, P ¼ 0.004), indicating potentially altered engraftment behavior of vav2 À / À cells. In summary, here we describe a potential method how to prioritize the large numbers of HOX-controlled genes in order to search for targets with increased biological relevance in HSPC. We validated this approach by identifying Vav2 and therefore Rac1 activity to be under HOX control. Rac1, a member of the Rho superfamily of small GTPases, is widely involved in hematopoietic development and it is particularly important for control of HSPC-specific properties such as engraftment and homing, as well as for proper interaction with the microenvironment. 15 
